Megan Kruse

3 weeks ago | targetedonc.com | Virginia Kaklamani |Megan Kruse

Video content above is prompted by the following: Clinical Brief: ESR1 Testing and Hormone Receptor-Positive Metastatic Breast Cancer Main Discussion Topics: Introduction to ESR1 mutations in metastatic breast cancer, occurring in 40% to 50% of patients treated with anti-estrogen therapy Mechanism of ESR1 mutations: allowing cancer cells to act as though estrogen is present even without it Importance of testing for ESR1 mutations at different points during the treatment journey Introduction...

3 weeks ago | targetedonc.com | Virginia Kaklamani |Megan Kruse

Video content above is prompted by the following: Clinical Brief: Biomarker Testing Strategy in Second-Line Therapy Main Discussion Topics: Strategic approach to biomarker testing when transitioning to second-line therapy Importance of liquid biopsy versus tissue biopsy for ESR1 mutation detection Role of PIK3CA and other pathway mutations in treatment selection Shared decision-making process for selecting between multiple treatment options Clinical assessment of endocrine sensitivity...

3 weeks ago | targetedonc.com | Virginia Kaklamani |Megan Kruse

Video content above is prompted by the following: Clinical Brief: EMERALD Trial Insights for ESR1-Mutant Breast Cancer Main Discussion Topics: Overview of EMERALD trial design and patient population Co-primary end points and efficacy outcomes for ESR1-mutant tumors Critical subset analyses identifying best responders (>12 months prior CDK4/6) Median PFS outcomes: 8.6 months versus 3.8 months in optimal patients Limited relevance of variant allele frequency (VAF) for treatment selection Key...

3 weeks ago | targetedonc.com | Virginia Kaklamani |Megan Kruse

Video content above is prompted by the following: Clinical Brief: Elacestrant Subgroup Benefits and Safety Profile Main Discussion Topics: Efficacy across different disease sites (bone-only versus visceral) Impact of tumor burden (multiple sites of metastasis) Co-mutation status (PIK3CA, p53) and treatment efficacy Safety profile focusing on gastrointestinal (GI) tolerability and lipid monitoring FDA recommendation for lipid profile monitoring requirements Key Points for Physicians:...

3 weeks ago | targetedonc.com | Virginia Kaklamani |Megan Kruse

Video content above is prompted by the following: Clinical Brief: Second-Line Treatment Decision Framework Main Discussion Topics: Integration of patient factors in treatment selection Balance between efficacy and quality-of-life considerations Practical considerations: insurance, copays, administration route Sequential versus concurrent treatment strategies Role of shared decision-making in complex treatment landscape Key Points for Physicians: Treatment selection requires balance of...